BIOMAT Database Logo BIOMAT Database Logo

Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator. 1990

R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Department of Medicine, University of Manitoba, Winnipeg, Canada.

We compared thrombolytic and pulmonary hemodynamic effects of recombinant tissue plasminogen activator (rtPA) and urokinase (UK) in canine micropulmonary thromboembolism. Dogs were embolized with radioactive autologous blood clot to increase mean pulmonary artery pressure (from 13 to 34 mm Hg, p less than 0.005) and decrease cardiac output (2.5 to 1.6 L min, p less than 0.005). Four groups of six dogs were treated. We employed two doses of UK, 30,000 U/kg (UK30) and 60,000 U/kg (UK60), and two doses of rtPA, 1 mg/kg (rtPA1) and 2 mg/kg (rtPA2). Drugs were infused over 15 min. Rate and extent of pulmonary thrombolysis were assessed by continuously counting over both lung fields with a gamma camera. Compared with treatment with UK, both rtPA regimes significantly increased thrombolysis. Mean total pulmonary thrombolysis was 14 and 23% with UK30 and UK60, respectively, and 35 and 43% with rtPA1 and rtPA2. Corresponding to the increased thrombolysis, pulmonary hemodynamics improved most with rtPA. From 90 min to 3 h, pulmonary artery pressure was significantly lower with both rtPA regimes than with either UK regime. These results indicate, at least in the model employed, that compared with treatment with UK, pulmonary thrombolysis and corresponding hemodynamic improvement are greatest with rtPA.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism.
January 2017, Advances in experimental medicine and biology,
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Urokinase versus tissue plasminogen activator in pulmonary embolism.
October 1988, Lancet (London, England),
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Urokinase versus tissue plasminogen activator in pulmonary embolism.
September 1988, Lancet (London, England),
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
[Thrombolytic therapy of pulmonary artery embolism in early pregnancy with recombinant tissue-type plasminogen activator].
August 1991, Geburtshilfe und Frauenheilkunde,
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Thrombolytic therapy of massive pulmonary embolism during prolonged cardiac arrest using recombinant tissue-type plasminogen activator.
June 1989, Annals of emergency medicine,
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Successful thrombolytic therapy with recombinant tissue-type plasminogen activator for massive pulmonary embolism -A case report-.
July 2010, Korean journal of anesthesiology,
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
[The thrombolytic treatment of acute and subacute recurrent pulmonary embolism with recombinant tissue plasminogen activator].
November 1990, Deutsche medizinische Wochenschrift (1946),
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism.
July 1985, Annals of internal medicine,
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
June 1992, Chest,
R M Prewitt, and C Hoy, and A Kong, and S A Gu, and D Greenberg, and R Cook, and S M Chan, and J Ducas
[Recombinant DNA technology in thrombolytic therapy: tissue-type plasminogen activator].
March 1991, Bollettino chimico farmaceutico,
Copied contents to your clipboard!